Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label Study Evaluating the Safety and Efficacy of ST-067 in Combination With CD19-Directed CAR T-Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

NCT07098364 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT07098364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07098364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label Study Evaluating the Safety and Efficacy of ST-067 in Combination With CD19-Directed CAR T-Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1/2
Overall status
Suspended
Start date
December 27, 2025
Completion date
October 4, 2043
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent grade 3b follicular lymphoma, recurrent high-grade b-cell lymphoma, recurrent indolent b-cell non-hodgkin lymphoma, recurrent primary mediastinal large b-cell lymphoma, refractory diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory grade 3b follicular lymphoma, refractory high-grade b-cell lymphoma, refractory indolent b-cell non-hodgkin lymphoma, refractory primary mediastinal large b-cell lymphoma